Astrocyte Pharmaceuticals Inc. is a small drug development company dedicated to clinically proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients.
Background
Brain injuries are a substantial cause of death and disability worldwide. The brain is particularly vulnerable to damage as neurons have a limited capacity to repair, regardless if injury is caused by a severe or mild trauma such as a concussion, ischemic episodes such as stroke, or degenerative disorders such as Alzheimer’s Disease. As a result, traumatic brain injuries (TBI) and neurodegeneration often result in the debilitating and largely irreversible degradation of a patient’s cognitive and sensorimotor functions.

Astrocyte Pharmaceuticals is pursuing an innovative neuroprotective strategy to protect and repair neurons that are damaged by selectively stimulating astrocytes. This enables selective activation of their caretaker processes including the removal of harmful extracellular molecules and the restoration of ion homeostasis. The company is investigating and advancing small molecule pharmaceutical medicines that will provide neuroprotection to a range of brain injury patients.

Astrocyte Pharmaceuticals Inc. is a small drug development company dedicated to clinically proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury patients.

Background
Brain injuries are a substantial cause of death and disability worldwide. The brain is particularly vulnerable to damage as neurons have a limited capacity to repair, regardless if injury is caused by a severe or mild trauma such as a concussion, ischemic episodes such as stroke, or degenerative disorders such as Alzheimer’s Disease. As a result, traumatic brain injuries (TBI) and neurodegeneration often result in the debilitating and largely irreversible degradation of a patient’s cognitive and sensorimotor functions.

Astrocyte Pharmaceuticals is pursuing an innovative neuroprotective strategy to protect and repair neurons that are damaged by selectively stimulating astrocytes. This enables selective activation of their caretaker processes including the removal of harmful extracellular molecules and the restoration of ion homeostasis. The company is investigating and advancing small molecule pharmaceutical medicines that will provide neuroprotection to a range of brain injury patients.

For recent media coverage on Dr. James Lechleiter and the potential for a “concussion pill” for athletes (football, soccer, hockey, etc.), please see the news section.

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders